Innovations in soft tissue regenerative medical technology – Tissue Regenix

January 30, 2018

Spun out of the University of Leeds in 2006, Tissue Regenix commercialise upon research undertaken by our higher education and research partners around the world. Tissue Regenix listed on the Alternative Investment Market (AIM) on the London Stock Exchange in 2010, before opening the first subsidiary office Tissue Regenix Woundcare, Inc. in San Antonio, Texas in 2012.
Find out more about how Tissue Regenix’ patented dCELL Technology is being used in ’21st Century Healthcare’ in this short video, made in collaboration with the Royal Society of Medicine and ITN Productions.

The company’s patented decellularisation (‘dCELL®’) Technology removes DNA and other cellular material from tissue leaving intact an inert acellular matrix upon which the patients cells can repopulate.
The potential applications of dCELL® are diverse and address critical clinical needs such as; wound care, heart valve replacement and knee repair.
In early 2016, Tissue Regenix entered its first joint venture establishing GBM-V , a Tissue Bank in Rostock, Germany, granting them the first licence for the production of dCELL® heart valves, and strengthening its presence within Europe.